A 4-week trial documented significant reduction in ADHD symptoms when participants took Dasotraline compared to a placebo. Various side effects associated with this drug included appetite reduction, dry mouth, insomnia, and nausea.
EB-1020 is a novel drug in Phase II clinical trials for the treatment of ADHD. It is under development by Neurovance, a spinout from Euthymics Biosciences. The drug is intended to function as a non-stimulant, acting as a triple reuptake inhibitor – preventing the reuptake of dopamine, norepinephrine, and serotonin.
Sunovion Pharmaceuticals is investigating the efficacy of the drug Dasotraline (SEP-225289) for the treatment of adult ADHD. The drug functions as a triple reuptake inhibitor, increasing extracellular levels of serotonin, dopamine, and norepinephrine.
AR-08 is a drug under development by Arbor Pharmaceuticals for the treatment of ADHD among children and adolescents (between ages 6 and 17 years). While its exact mechanism of action hasn’t been made publicly available, it is known that AR-08 functions as an adrenergic receptor agonist.
There are many potential causes of ADHD, some of which are likely endogenous such as: genetics and brain anatomy. That said, there are also often exogenous factors such as: an unhealthy diet, improper sleep, poor parenting, lack of exercise, and brain injuries – that can often manifest ADHD symptoms.